Oncternal Therapeutics (NASDAQ:ONCT) is a biopharmaceutical company dedicated to developing innovative therapies for cancer treatment with a focus on addressing unmet medical needs. With an aim to extend and enhance the lives of patients suffering from cancer, Oncternal is currently engaging in several promising projects, including the development of targeted therapies that leverage the latest advancements in oncology research. The company's pipeline showcases a diverse range of investigational drugs, each designed to target specific mechanisms involved in the growth and spread of cancerous cells. Objectives at Oncternal include progressing clinical trials to eventually bring new, effective cancer treatments to market, improving patient outcomes, and establishing partnerships to enhance research and development capabilities.